The DOI matches its Crossref record.
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Abstract
OBJECTIVE: Psychotropic drugs often induce weight gain, leading to discomfort and discontinuation of treatment and, more importantly, increasing the risk of obesity-related illnesses such as diabetes mellitus, hypertension, and coronary heart disease. There is evidence that antidepressant drugs may induce a variable amount of weight gain, but results are sparse and often contradictory. DATA SOURCES: We performed a literature search using the MEDLINE, ISI Web of Knowledge, and Cochrane research databases for all publications available to January 2009. We used the following keywords: antidepressant, psychotropic drugs, body weight, weight gain, obesity, overweight, adverse event, side effects, SSRIs, tricyclic antidepressants, and the name of each antidepressant active compound together with body weight or other keywords. Studies reporting body weight changes during treatment with different antidepressants were selected for eligibility. Finally, 116 studies were included in the analysis. DATA EXTRACTION: Weight change mean and standard deviation and size of each group were recorded. Missing means and standard deviations were directly calculated by using information available in the article when possible. Non-placebo-controlled studies were compared to a virtual placebo sample, whose mean and standard deviation were derived by the weighted mean of means and standard deviations of all placebo samples. Methodological quality of studies, heterogeneity, publication bias, and effect of treatment duration were systematically controlled. DATA SYNTHESIS: Quantitative results evidenced that amitriptyline, mirtazapine, and paroxetine were associated with a greater risk of weight gain. In contrast, some weight loss occurs with fluoxetine and bupropion, although the effect of fluoxetine appears to be limited to the acute phase of treatment. Other compounds have no transient or negligible effect on body weight in the short term. However, the effect of each antidepressant may vary greatly depending on an individual's characteristics and generally became more evident in the long term to a variable degree across compounds. CONCLUSIONS: Despite the fact that some analyses were done on only a few studies due to the difficulty of finding reliable information in literature, to our knowledge, this is the first comprehensive meta-analysis to allow comparison of different antidepressants as regards their impact on body weight. Data presented may be helpful for a more accurate treatment selection in patients at risk of obesity or related medical illness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the persistence of some residual symptoms (e.g., cognitive and sleep disturbances)”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [5]
In the citing paper
“The sedative antidepressants may also induce a weight gain, what is particularly shown for mirtazapine but not for trazodone [23].”
From Effects of Antidepressants on Sleep (2017) · cites this paper as [23]
In the citing paper
“Amitriptyline and mirtazapine consistently showed weight gaining effects throughout acute and long-term treatment.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
In the citing paper
“A meta-analysis further showed that SSRIs including citalopram, escitalopram, fluoxetine, sertraline, paroxetine and SNRIs including venlafaxine and duloxetine were associated with weight loss compared with placebo.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
In the citing paper
“Imipramine and bupropion showed significant weight loss effects for both acute and long term treatment (Table 5).70”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [70]
Citations
Cited by
Sorted by citations
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“SSRIs such as fluoxetine and sertraline have been associated with weight loss during acute treatment (4–12 wk) and with weight neutrality in the maintenance ( 4 mo) phase (99).”
BackgroundInfluentialDepression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment
Fang, H., Tu, S., Sheng, J., & Shao, A. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14170 · Cited by 1,225
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Some antidepressants, including amitriptyline, mirtazapine, and paroxetine have also been associated with weight gain [1448].”
BackgroundDepression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“monozygotic twin and sibling studies, suggests that genetic factors play an important role in medication-induced weight gain (43-45), with estimates as high as 60-80% for antipsychotic-related weight gain (46).”
BackgroundCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 646
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Effects of Antidepressants on Sleep
Wichniak, A., Wierzbicka, A., Walęcka, M., & Jernajczyk, W. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0816-4 · Cited by 557
Holt, R. I. G., de Groot, M., & Golden, S. H. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0491-3 · Cited by 552
McCarron, R. M., Shapiro, B. B., Rawles, J., & Luo, J. S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202105180 · Cited by 511
Mutz, J., Vipulananthan, V., Carter, B., Hurlemann, R., Fu, C. H. Y., & Young, A. H. (2019) · BMJ · doi:10.1136/bmj.l1079 · Cited by 427
Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression
Milaneschi, Y., Lamers, F., Berk, M., & Penninx, B. W. J. H. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.014 · Cited by 451
Endocrine disruptors and obesity
Heindel, J. J., Newbold, R., & Schug, T. T. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.163 · Cited by 451
Obesity and cognitive decline: role of inflammation and vascular changes
Nguyen, J. C. D., Killcross, S., & Jenkins, T. A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00375 · Cited by 440
Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule
Yabut, J. M., Crane, J. D., Green, A. E., Keating, D. J., Khan, W. I., & Steinberg, G. R. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00283 · Cited by 436
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Obstructive Sleep Apnea and Psychiatric Disorders: A Systematic Review
Gupta, M. A., & Simpson, F. C. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4466 · Cited by 367
“85–87 The association between obesity and psychiatric medication is well known, 79,82,85,87,88 but the direct effects of these drugs on the upper airway and breathing during sleep are important factors.”
Interventions for preventing weight gain after smoking cessation
Farley, A., Hájek, P., Lycett, D., & Aveyard, P. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 340
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D. M., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 343
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
“Imipramine and bupropion showed significant weight loss effects for both acute and long term treatment (Table 5).(70) A more recent study using electronic health records showed even more conflicting results.”
ResultThe interface of depression and obesity
Jantaratnotai, N., Mosikanon, K., Lee, Y., & McIntyre, R. S. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2016.07.003 · Cited by 282
Regulation of systemic energy homeostasis by serotonin in adipose tissues
Oh, C., Namkung, J., Go, Y., Shong, K. E., Kim, K., Kim, H., Park, B.-Y., Lee, H. W., Jeon, Y. H., Shong, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7794 · Cited by 271
Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
Stuart, M. J., & Baune, B. T. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.10.001 · Cited by 257
Side effects of antidepressants during long-term use in a naturalistic setting
Bet, P. M., Hugtenburg, J. G., Penninx, B. W. J. H., & Hoogendijk, W. J. G. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.001 · Cited by 239
“A recent meta-analysis showed large differences in weight gain between individuals as the result of treatment with various antidepressants (Serretti and Mandelli, 2010).”
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
“In a recent meta-analysis, the antidepressants amitriptyline, mirtazapine, and paroxetine were associated with the greatest risk of weight gain, with other investigated antidepressants having only transient or negligible effects on body weight in the short term (Serretti and Mandelli, 2010).”
BackgroundCitrome, L. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02885.x · Cited by 228
Treatment of sleep disturbances in posttraumatic stress disorder: A review
Schoenfeld, F. B., DeViva, J. C., & Manber, R. (2012) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2011.09.0164 · Cited by 228
“risk for weight gain, which in addition to other health risks can also increase the risk for new onset and exacerbation of sleep apnea (Serretti and Mandelli [89]).”
BackgroundHiles, S. A., Baker, A., de Malmanche, T., & Attia, J. (2012) · Psychological Medicine · doi:10.1017/s0033291712000128 · Cited by 224
Oliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., & Serretti, A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110266 · Cited by 219
Self-citationTreating comorbid anxiety and depression: psychosocial and pharmacological approaches
Coplan, J. D. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i4.366 · Cited by 207
Robinson, D. J., Coons, M., Haensel, H., Vallis, M., & Yale, J.-F. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.031 · Cited by 209
Gafoor, R., Booth, H., & Gulliford, M. C. (2018) · BMJ · doi:10.1136/bmj.k1951 · Cited by 207
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12298 · Cited by 204
Antidepressant Medications and Weight Change: A Narrative Review
Gill, H., Gill, B., El‐Halabi, S., Chen-Li, D. C. J., Lipsitz, O., Rosenblat, J. D., Rheenen, T. E. V., Rodrigues, N. B., Mansur, R. B., Majeed, A., et al. (2020) · Obesity · doi:10.1002/oby.22969 · Cited by 209
“69 kg) ≥ 4 months following treatment (35).”
BackgroundResultInfluentialPolygenic dissection of major depression clinical heterogeneity
Milaneschi, Y., Lamers, F., Peyrot, W. J., Abdellaoui, A., Willemsen, G. A. H. M., Hottenga, J., Jansen, R., Mbarek, H., Dehghan, A., Lu, C., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.86 · Cited by 183
Paroxetine for the treatment of depression: a critical update
Gibiino, S., & Serretti, A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.652085 · Cited by 180
“2% decrease) and in a recent review paroxetine was found to determine a marginal weight loss during acute treatment (4 -- 8 weeks), whilst in the medium-long term it has been associated with weight gain, significantly at 8 months of treatment [90].”
BackgroundSelf-citationAntidepressant Medication as a Risk Factor for Type 2 Diabetes and Impaired Glucose Regulation
Barnard, K. D., Peveler, R., & Holt, R. I. G. (2013) · Diabetes Care · doi:10.2337/dc13-0560 · Cited by 172
“Recently, there have been concerns that antidepressants may adversely affect glucose metabolism, not least because some antidepressants induce significant weight gain, which may contribute to insulin resistance (2).”
BackgroundObesity, adipokines and neuroinflammation
Aguilar‐Valles, A., Inoue, W., Rummel, C. D., & Luheshi, G. N. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.023 · Cited by 173
“…as amitriptyline, mirtazapine, and paroxetine and atypical antipsychotics such as clozapine and olanzapine, although other similar medication have only transient or negligible effects on body weight (Gautam and Meena, 2011; Newcomer, 2005; Rummel-Kluge et al., 2010; Serretti and Mandelli, 2010).”
BackgroundAn Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use
Blumenthal, S. R., Castro, V. M., Clements, C. C., Rosenfield, H. R., Murphy, S. N., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.414 · Cited by 151
Holt, R. I. G., de Groot, M., Lucki, I., Hunter, C. M., Sartorius, N., & Golden, S. H. (2014) · Diabetes Care · doi:10.2337/dc13-2134 · Cited by 155
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
“effects and, together with sertraline, is thought to be associated with the least weight gain of the SSRIs (Serretti and Mandelli, 2010).”
BackgroundP2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes
Wang, D., Wang, H., Gao, H., Zhang, H., Zhang, H., Wang, Q., & Sun, Z. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00388-1 · Cited by 151
Sleep and Antidepressant Treatment
Wichniak, A., Wierzbicka, A., & Jernajczyk, W. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523608 · Cited by 142
“[108] Serretti A, Mandelli L.”
Is increased antidepressant exposure a contributory factor to the obesity pandemic?
Lee, S. H., Paz-Filho, G., Mastronardi, C. A., Licinio, J., & Wong, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.25 · Cited by 145
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 141
Adipokines as emerging depression biomarkers: A systematic review and meta-analysis
Carvalho, A. F., Rocha, D. Q. C., McIntyre, R. S., Mesquita, L. M., Köhler, C. A., Hyphantis, T. N., Sales, P. M. G., Machado‐Vieira, R., & Berk, M. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.002 · Cited by 138
Robinson, D. J., Luthra, M., & Vallis, M. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.026 · Cited by 142
“A comprehensive review and meta-analysis looked at the effect of antidepressants on body weight (51).”
BackgroundEffects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults
Deuschle, M. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835a4206 · Cited by 130
“A recent meta-analysis showed amitriptyline, mirtazapine, and paroxetine to be especially related to weight gain, whereas fluoxetine and bupropion may lead to some weight loss, at least in the short run [18].”
BackgroundCardiometabolic effects of psychotropic medications
Abosi, O. J., Lopes, S., Schmitz, S. L., & Fiedorowicz, J. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0065 · Cited by 135
A comprehensive diagnostic approach to detect underlying causes of obesity in adults
van der Valk, E. S., van den Akker, E. L. T., Savas, M., Kleinendorst, L., Visser, J. A., van Haelst, M. M., Sharma, A. M., & van Rossum, E. F. C. (2019) · Obesity Reviews · doi:10.1111/obr.12836 · Cited by 138
“The strongest weight change is seen in amitriptyline, mirtazapine, and paroxetine.(39) As for antipsychotic drugs, olanzapine and clozapine induce the highest weight gain.”
BackgroundDiet, Obesity, and Depression: A Systematic Review
Patsalos, O., Keeler, J. L., Schmidt, U. H., Penninx, B. W. J. H., Young, A. H., & Himmerich, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030176 · Cited by 136
Haneuse, S., & Daniels, M. J. (2016) · eGEMs (Generating Evidence & Methods to improve patient outcomes) · doi:10.13063/2327-9214.1203 · Cited by 118
“, paroxetine and mirtazapine), the existing literature is limited in that it focuses on short-term outcomes of 12 months or less.(25-29) Given the lack of evidence regarding long-term outcomes we took weight change at 24 months posttreatment initiation to be the primary outcome.”
BackgroundRaman, J., Smith, E., & Hay, P. (2013) · Journal of Obesity · doi:10.1155/2013/240128 · Cited by 120
“The exact nature of the relationship between depression and obesity maintenance remains unclear, perhaps because clinical depression is a common exclusion criterion in weight-loss intervention trials [78, 79].”
BackgroundImmuno-metabolic depression: from concept to implementation
Penninx, B. W. J. H., Lamers, F., Jansen, R., Berk, M., Khandaker, G. M., Picker, L. D., & Milaneschi, Y. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101166 · Cited by 131
“In, contrast, bupropion, for instance, has been found to lower weight during acute and maintenance phases of treatment, 71 and has been FDA-approved for obesity treatment because of its weight-loss inducing properties.”
Peripheral Serotonin: a New Player in Systemic Energy Homeostasis
Namkung, J., Kim, H., & Park, S. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0258 · Cited by 121
“In addition, the enhancement of serotonin activity using a selective SERT inhibitor (SSRI) is associated with transient weight loss (Serretti and Mandelli, 2010).”
Verhoeven, J. E., Han, L. K. M., Lever-van Milligen, B. A., Hu, M. X., Révész, D., Hoogendoorn, A. W., Batelaan, N. M., van Schaik, D. J. F., van Balkom, A. J. L. M., van Oppen, P., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.064 · Cited by 112
Psychotropic Drug–Related Weight Gain and Its Treatment
McIntyre, R. S., Kwan, A. T. H., Rosenblat, J. D., Teopiz, K. M., & Mansur, R. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230922 · Cited by 128
The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors
Hamad, G. G., Helsel, J. C., Perel, J. M., Kozak, G. M., McShea, M. C., Hughes, C., Confer, A. L., Sit, D. K. Y., McCloskey, C. A., & Wisner, K. L. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11050719 · Cited by 112
“Psychotropic medications (5) and atypical depressive symptoms such as overeating and fatigue contribute to weight gain.”
BackgroundConnecting insufficient sleep and insomnia with metabolic dysfunction
Duan, D., Kim, L. J., Jun, J. C., & Polotsky, V. Y. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14926 · Cited by 110
Weight gain and associated factors in patients using newer antidepressant drugs
Uğuz, F., Şahingöz, M., Güngör, B. B., Aksoy, F., & Aşkın, R. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.10.011 · Cited by 106
Kunugi, H. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13551 · Cited by 117
Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature
Dent, R., Blackmore, A., Peterson, J., Habib, R., Kay, G. P., Gervais, A., Taylor, V. H., & Wells, G. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036889 · Cited by 113
“Three articles [55,67,68] provided controversy in the ranking between paroxetine and mirtazapine.”
BackgroundOluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“Although adverse events are associated with all drugs, specific antidepressants are associated with higher rates of particularly troublesome side effects, such as weight gain and sexual dysfunction (Ashton et al., 2005; Serretti and Chiesa, 2009; Serretti and Mandelli, 2010; Clayton et al., 2014).”
BackgroundBly, M. J., Taylor, S. F., Dalack, G. W., Pop‐Busui, R., Burghardt, K. J., Evans, S. J., McInnis, M. G., Grove, T. B., Brook, R. D., Zöllner, S. K., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12160 · Cited by 106
“In general, bupropion has not been associated with significant weight gain, while citalopram may be associated with some weight gain with long-term use (44, 45).”
BackgroundMedications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
Interventions for preventing weight gain after smoking cessation
Hartmann‐Boyce, J., Theodoulou, A., Farley, A., Hájek, P., Lycett, D., Jones, L. L., Kudlek, L., Heath, L., Hajizadeh, A., Schenkels, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub4 · Cited by 100
Obesity as pleiotropic risk state for metabolic and mental health throughout life
Leutner, M., Dervic, E., Bellach, L., Klimek, P., Thurner, S., & Kautzky, A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02447-w · Cited by 93
“Another confounding factor are iatrogenic effects mediated by antidepressant and even more so antipsychotic medication [20, 35].”
BackgroundHasnain, M., Vieweg, W. V. R., & Hollett, B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2577 · Cited by 96
Kronish, I. M., Carson, A. P., Davidson, K. W., Muntner, P., & Safford, M. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052771 · Cited by 93
“For example, some antidepressants have been associated with weight gain [35] and blood pressure changes.”
BackgroundOverweight and obesity in youth with developmental disabilities: a call to action
Grondhuis, S. N., & Aman, M. G. (2013) · Journal of Intellectual Disability Research · doi:10.1111/jir.12090 · Cited by 104
Distinguishing Selection Bias and Confounding Bias in Comparative Effectiveness Research
Haneuse, S. (2013) · Medical Care · doi:10.1097/mlr.0000000000000011 · Cited by 94
“Although the processes underlying their impact on health outcomes are the subjects of much recent research, there is growing evidence that the choice of antidepressant drug therapy influences changes in weight over time.(23,24) With climbing rates of obesity(17) and antidepressant agents being the most commonly prescr…”
BackgroundBeyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness
Taylor, V. H., McIntyre, R. S., Remington, G. J., Levitan, R. D., Stonehocker, B., & Sharma, A. M. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700103 · Cited by 94
Isomura, K., Brander, G., Chang, Z., Kuja‐Halkola, R., Rück, C., Hellner, C., Lichtenstein, P., Larsson, H., Mataix‐Cols, D., & de la Cruz, L. F. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.003 · Cited by 91
Eating Disorders in Schizophrenia: Implications for Research and Management
Kouidrat, Y., Amad, A., Lalau, J., & Loas, G. (2014) · Schizophrenia Research and Treatment · doi:10.1155/2014/791573 · Cited by 87
“Indeed, in addition to antipsychotics, patients often consume anxiolytics, antidepressants, and other mood stabilizers with well-documented side effects of increased appetite and weight gain [72].”
BackgroundWeight Considerations in Psychotropic Drug Prescribing and Switching
Hasnain, M., & Vieweg, W. V. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2706 · Cited by 86
Hung, C., Rivera, M., Craddock, N. J., Owen, M. J., Gill, M., Korszun, A., Maier, W., Mors, O. N., Preisig, M., Rice, J. P., et al. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.130419 · Cited by 84
“A meta-analysis 30 suggested that some antidepressants might cause weight change during long-term treatment.”
Dionysopoulou, S., Charmandari, E., Bargiota, Α., Vlahos, N., Mastorakos, G. P., & Valsamakis, G. (2021) · Nutrients · doi:10.3390/nu13020498 · Cited by 91
Beyazyüz, M., Albayrak, Y., Eğilmez, O. B., Albayrak, N., & Beyazyüz, E. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.2.148 · Cited by 83
“It’s those Pills that are Ruining Me”
Littlejohn, K. E. (2013) · Gender & Society · doi:10.1177/0891243213504033 · Cited by 85
Tran, P., Skolnick, P., Czobor, P., Huang, N. Y., Bradshaw, M., McKinney, A., & Fava, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.003 · Cited by 81
“Weight changes, especially weight gain, are unwanted side effects of many antidepressants and may contribute to co-morbidities and non-adherence to treatment regimens (Fava, 2000; Serretti and Mandelli, 2010).”
BackgroundBartoli, F., Trotta, G., Crocamo, C., Malerba, M. R., Clerici, M., & Carrà, G. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0817-7 · Cited by 82
The Impact of General Medical Conditions in Obsessive-Compulsive Disorder
Aguglia, A., Signorelli, M. S., Albert, U., & Maina, G. (2018) · Psychiatry Investigation · doi:10.30773/pi.2017.06.17.2 · Cited by 82
The interface of depression and diabetes: treatment considerations
Fanelli, G., Raschi, E., Hafez, G., Matura, S., Schiweck, C., Poluzzi, E., & Lunghi, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03234-5 · Cited by 112
Branco‐de‐Almeida, L. S., Franco, G. C. N., Castro, M. L., et al. (2011) · Journal of Periodontology · doi:10.1902/jop.2011.110370 · Cited by 80
The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
Salvi, V., Grua, I., Cerveri, G., Mencacci, C., & Barone‐Adesi, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182088 · Cited by 85
Musculoskeletal Pain, Fear Avoidance Behaviors, and Functional Decline in Obesity
Vincent, H. K., Adams, M. C. B., Vincent, K. R., & Hurley, R. W. (2013) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000013 · Cited by 84
“Nortriptyline was associated with modest weight gain with acute (<12 weeks) use but not when used longer than 4 months.(110) Interestingly, a systematic review of adverse events associated with the use of antidepressants as a class found higher depression severity and 3 or more comorbid psychiatric diagnoses were asso…”
BackgroundInfluentialBai, Y., Su, T., Chen, M., Chen, T., & Chang, W.-H. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.02.019 · Cited by 81
“Another factor is the treatment of antidepressants, previous research evidences have shown long-term effect of antidepressants on metabolic side effects may vary greatly depending on the individual’s characteristics, and some antidepressants, such as fluoxetine and bupropion, have been reported to reduce body weight (…”
BackgroundPharmacological strategies for targeting BAT thermogenesis
Whittle, A. J., Relat, J., & Vidal‐Puig, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.004 · Cited by 82
Treatment of Depression in Patients with Concomitant Cardiac Disease
Teply, R. M., Packard, K. A., White, N. D., Hilleman, D. E., & DiNicolantonio, J. J. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.11.003 · Cited by 78
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder
Alam, M. Y., Jacobsen, P. L., Chen, Y., Serenko, M., & Mahableshwarkar, A. R. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000010 · Cited by 76
“…increase in mean weight in study participants treated with vortioxetine during this study was comparable with that observed in the placebo group (0.8 kg) of a meta-analysis of long-term (> 8 months) placebo-controlled clinical studies that involved 12 antidepressants (Serretti and Mandelli, 2010).”
BackgroundResultInfluentialSerretti, A. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.1.1 · Cited by 76
“1 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2018;16(1):1-6 Copyrightc 2018, Korean College of Neuropsychopharmacology”
BackgroundSelf-citationVortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
Baldwin, D. S., Hansen, T. F., & Florea, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.725035 · Cited by 73
Effect of caloric restriction on depression
Manchishi, S. M., Cui, R., Zou, X. H., Cheng, Z. Q., & Li, B. J. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13418 · Cited by 71
“Conversely, though other studies suggest that BDNF does not play an essential role in the regulation of energy expenditure [72], BDNF-deficient mice show hyperphagia and consequent obesity [73].”
BackgroundRobinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Sterke, S., Ziere, G. J., van Beeck, E. F., Looman, C. W. N., & van der Velde, N. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04124.x · Cited by 73
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 74
“antidepressants, the so-called selective serotonin reuptake inhibitors, have modest effects on body weight in short-term trials.(209,210) However, with long-term use of these drugs in general,”
BackgroundVerhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 75
Metadata
- Authors
- Serretti, A., & Mandelli, L.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Serretti, Alessandro
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-10-15
- Volume
- 71
- Issue
- 10
- Pages
- 1259-1272
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2030270520
- Cited by
- 621
- References
- 0
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 46 · 2023: 41 · 2022: 42 · 2021: 41 · 2020: 33 · 2019: 36 · 2018: 37 · 2017: 36 · 2016: 31 · 2015: 47 · 2014: 40 · 2013: 49 · 2012: 41
- FWCI
- 25.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- antidepressants, weight gain, body weight, psychotropic drugs, obesity, amitriptyline, mirtazapine, paroxetine, fluoxetine, bupropion, tricyclic antidepressants, selective serotonin reuptake inhibitors, adverse drug reactions, treatment discontinuation
- MeSH terms
- Antidepressive Agents, Body Weight, Clinical Trials as Topic, Humans, Time Factors, Weight Gain, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
